• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Mates Sharon

    11/7/25 7:48:58 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BNTC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Mates Sharon

    (Last) (First) (Middle)
    C/O BENITEC BIOPHARMA INC.
    3940 TRUST WAY

    (Street)
    HAYWARD CA 94545

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/03/2025
    3. Issuer Name and Ticker or Trading Symbol
    Benitec Biopharma Inc. [ BNTC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Sharon Mates 11/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BNTC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNTC

    DatePrice TargetRatingAnalyst
    7/7/2025Buy
    TD Cowen
    12/16/2024$28.00Buy
    H.C. Wainwright
    12/13/2024$30.00Outperform
    Robert W. Baird
    10/16/2024$35.00Outperform
    Oppenheimer
    9/12/2024$17.00Buy
    Guggenheim
    7/22/2024$13.00Outperform
    Leerink Partners
    6/13/2024$30.00Overweight
    Piper Sandler
    2/17/2022$10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BNTC
    SEC Filings

    View All

    SEC Form 8-K filed by Benitec Biopharma Inc.

    8-K - Benitec Biopharma Inc. (0001808898) (Filer)

    11/6/25 9:29:10 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Benitec Biopharma Inc.

    424B5 - Benitec Biopharma Inc. (0001808898) (Filer)

    11/6/25 9:26:08 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Benitec Biopharma Inc.

    424B5 - Benitec Biopharma Inc. (0001808898) (Filer)

    11/5/25 5:17:07 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

    HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference ("ddRNAi") "Silence and Replace" platform, today announced the pricing of its underwritten public offering of 5,930,000 shares of its common stock and a concurrent registered direct offering of 1,481,481 shares of its common stock with long-term investor Suvretta Capital. Each share of common stock is being sold at an offering price of $13.50. In addition, the Company has granted the underwriters a 30-day option to purchase

    11/6/25 12:19:46 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Inc. Announces Proposed Public Offering

    HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference ("ddRNAi") "Silence and Replace" platform, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and intends to conduct a concurrent registered direct offering of its common stock with long-term investor Suvretta Capital. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to a number o

    11/5/25 4:43:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

    Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted Orphan Drug Designation from both FDA and EMA All six patients enrolled into Cohort 1 met the formal statistical criteria for response to BB-301, representing a 100% response rate Following the administration of BB-301, Cohort 1 patients experienced significant continuing reductions in dysphagic symptom burden, post-swallow residue accumulation, time required to consume fixed volumes of liquid, and improved pharyngeal closure during swallowing First patient in Cohort 2 succ

    11/3/25 7:10:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Suvretta Capital Management, Llc bought $211,736 worth of shares (16,497 units at $12.83) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    4/2/25 4:37:02 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $11,700,000 worth of shares (900,000 units at $13.00) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    3/28/25 4:51:41 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $527,174 worth of shares (47,520 units at $11.09) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/26/24 4:28:03 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Benitec Biopharma

    TD Cowen initiated coverage of Benitec Biopharma with a rating of Buy

    7/7/25 8:17:08 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Benitec Biopharma with a new price target

    H.C. Wainwright initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $28.00

    12/16/24 6:46:22 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Robert W. Baird initiated coverage on Benitec Biopharma with a new price target

    Robert W. Baird initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $30.00

    12/13/24 7:25:56 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mates Sharon

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    11/7/25 7:50:02 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Mates Sharon

    3 - Benitec Biopharma Inc. (0001808898) (Issuer)

    11/7/25 7:48:58 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $211,736 worth of shares (16,497 units at $12.83) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    4/2/25 4:37:02 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Leadership Updates

    Live Leadership Updates

    View All

    Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

    HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Dr. Sharon Mates to the board of directors (BOD) of the Company, effective November 2, 2025. "We are delighted to welcome Dr. Sharon Mates to Benitec's Board of Directors," said Jerel Banks, M.D., Ph.D., Chairman and Chief Executive Officer of Benitec Biopharma. "Dr. Mates brings exceptional leadership experience in building successful biotechnology c

    11/3/25 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

    HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

    7/1/24 7:00:00 AM ET
    $BHVN
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Financials

    Live finance-specific insights

    View All

    Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

    Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 HAYWARD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its full year ended June 30, 2025. The Company has filed its annual report on Form 10-K with the U.S. Securities and Exchange Commi

    9/22/25 4:05:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Releases Third Quarter 2025 Financial Results

    HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its third fiscal quarter ended March 31, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission. "We are profoundly honored to be closely engaged with the OPMD patient community and are thankful for the support of the Subjects and their families as we remain focused on the continued development

    5/14/25 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

    -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024. The Company has filed its

    2/14/25 8:10:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Benitec Biopharma Inc.

    SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

    11/18/24 4:36:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    11/14/24 1:37:20 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care